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OBJECTIVES: The cross-sectional life-years lost (LYL)
index is commonly used to estimate years of life losses at
a speciﬁc point in time. However, the deaths included 
in such index have already occurred and are no longer
preventable. We sought to develop and use a potentially
more valuable measure, the expected remaining lifetime
years of potential life lost (i.e., LYPLL), for 21 major
cancers. METHODS: To estimate LPYLL, we used life
table techniques, U.S. population data from the U.S.
Bureau of the Census, and Surveillance, Epidemiology,
and End Results (SEER) data on the cancer-speciﬁc, age-
speciﬁc incidence and relative survival rates. We then
compared the resultant ﬁndings with published cross-
sectional LYL from SEER. RESULTS: The total number
of LYPLL per cancer ranged from 128,000 years
(Hodgkin’s lymphoma) to 2,055,000 years (lung/
bronchus cancer). The three leading causes of LYPLL
were lung/bronchus, female breast, colon/rectum, and
prostate cancer. In comparison, lung/bronchus, colon/
rectum, female breast, and pancreatic cancer were the
three leading causes of cross-sectional LYL. The average
LYPLL per cancer case ranged from 3.8 (prostate cancer)
to 16.8 years (Hodgkin’s lymphoma). Hodgkin’s lym-
phoma, brain and cervix cancer had the highest LYPLL
per case (16.8, 16.5, and 15.7 LYPLL per case, respec-
tively). The undiscounted LYPLL calculation results in a
similar rank in all cancers, with LYPLL of 3,144, 2,814,
and 1,993 thousand years for female breast, lung/
bronchus, colon/rectum, and prostate cancer, respectively.
CONCLUSIONS: The longitudinal LYPLL measure may
be more relevant than cross-sectional LYL index when
setting preventive intervention priority and goals. A
natural extension of the LYLLP method could be used to
better understand the economic burden of cancer and the
potential quality-adjusted life years lost. Ultimately, this
information could be used to determine more deﬁnitively
the cost-effectiveness of cancer prevention strategies (e.g.,
smoking cessation programs and cancer screening tech-
nologies and policies).
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OBJECTIVES: To evaluate healthcare expenditures asso-
ciated with treatment of seven TOI and deﬁne a burden
of TOI to the healthcare. METHODS: Retrospective
case-control study was conducted using MarketScanTM
claims databases of over 3 million US employees, spouses,
dependents, and early retirees. Cases were newly diag-
nosed with TOI in 1999–2000 (index date). Cases had no
cancer diagnosis for 12 months prior to index date and
had conﬁrming diagnosis of TOI within 3 months of the
index date. Control groups were members without cancer
diagnosis and matched 3:1 with each case group (97.5%
match) on gender, age, health coverage, region, and
follow-up period. Monthly healthcare expenditures were
estimated, adjusting for age, gender, Charlson Comor-
bidity Index, region, follow-up period, and hospital 
mortality using ordinary least squares with logarithmic
transformation. Due to left-skewed distribution, regres-
sion-adjusted expenditures of controls were estimated
using two-part models. Re-transformed expenditures
(using smearing estimator) were compared with a t-test.
RESULTS: The study consisted of 12,709 cases and
38,127 controls. Cases included 43% prostate, 22% 
colorectal, 16% lung, 5% brain, 3% ovarian and 3%
pancreatic cancer, and 8% Non-Hodgkin’s lymphoma
patients. Mean follow-up period was 11 months. Mean
monthly healthcare expenditures for cases were $3905
(SD = $2647) vs. $329 (SD = $446) for controls (p <
0.0001). The highest expenditures were associated with
pancreatic ($7613 vs. controls $334), ovarian ($6373 vs.
controls $281), brain ($6364 vs. controls $277), and lung
($6520 vs. controls $339) cancer. Except in prostate
cancer, inpatient services drove the expenditures in all
TOI. CONCLUSIONS: Mean monthly healthcare expen-
ditures associated with TOI were almost 12 times higher
compared to controls. Pancreatic, ovarian and brain
cancer patients had 20 times higher expenditures than
control groups. The burden of the seven tumors to the
healthcare system is substantial and suggests a need for
increased prevention or new therapies to reduce resource
use and healthcare expenditures.
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OBJECTIVES: For purposes of a payment policy, the
Centers for Medicare and Medicaid Services (CMS) have
adopted a dose conversion ratio (DCR) of 260 U epoetin
alfa (EPO) to 1 mcg darbepoetin alfa (DARB). A meta-
analysis was conducted based on all available clinical trial
information to estimate a DCR at which the two drugs
were equally effective in increasing hemoglobin levels in
patients with chemotherapy-induced anemia (CIA), mea-
sured by the area under the curve (AUC) of hemoglobin
change at weeks 4 and 13. METHODS: A search of
PUBMED, CANCERLIT and references for papers and
abstracts reporting on clinical trials of DARB or EPO in
treating CIA resulted in the identiﬁcation of 49 publica-
tions. Eleven papers met prospective criteria for eligibil-
ity in the meta-analysis, which included employing a
prospective study design and reporting baseline hemo-
globin concentration, change in hemoglobin concentra-
tion, tumor type and either mean dose of study drug or
proportion of patients requiring dose escalation. The
DCR is based on the ratio of the coefﬁcients on DARB
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and EPO doses in a regression of AUC on those two vari-
ables, baseline hemoglobin, and tumor type. Studies were
frequency-weighted by the number of subjects. DCRs
with conﬁdence intervals were calculated using a Monte-
Carlo approach. Similar regressions were conducted 
to compare EPO three-times-weekly (TIW) with DARB
once-weekly (QW) and DARB every-other-week (Q2W)
and to compare EPO QW with DARB QW and DARB
Q2W. RESULTS: The regression suggests a DCR of 166
(95% CI: 110–253). The comparison of EPO TIW to
DARB QW and DARB Q2W yields DCRs of 180
(107–243) and 170 (101–233), respectively. The com-
parison of EPO QW to DARB QW and DARB Q2W
results in DCRs of 116 (-16–185) and 173 (146–196).
CONCLUSION: The DCR of 260:1 estimated for
payment purposes is somewhat greater than the DCRs
estimated based on AUC.
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OBJECTIVE: Cervical cancer is preventable. However in
the Philippines, cervical cancer incidence remain signiﬁ-
cant with an overall survival rate of 44% in 5 years and
about 10/100,000 women dying after 5 years. Limited
resources, insufﬁcient screening infrastructure and inade-
quate treatment services have all led to an inability of less-
developed countries like the Philippines to implement 
an extensive cytology-based cervical cancer screening
program. Our objective is to identify and recommend a
cost-effective approach towards early detection of pre-
cursor lesions and early stage cervical cancer for the
Philippines. METHODS: This economic evaluation inves-
tigated four screening methods namely: acetic acid eval-
uation (AA), magniﬁed acetic acid visualization (MAA),
Pap smear using spatula + cotton swab (SS) and Pap
smear using a cervix brush (CB). It was undertaken 
concurrently with a standard criterion study involving a
nationwide sample of 9 secondary and tertiary hospitals,
5 community health centers and their catchment areas.
Cost per woman screened, cost per precursor/early 
cancer lesion detected, and cost per life saved in 5 years
were calculated using a societal perspective, 8% discount
rate and 1998 as base year. RESULTS: Cost per woman
screened is highest for CB and lowest for AA, at both 
hospital (CB = 631.61PHP/15.44USD; SS = 607.52PHP/
14.86USD; MAA = 478.80PHP/11.71USD; AA =
476.31PHP/11.65USD) and health center settings (CB =
425.34PHP/10.40USD; SS = 401.24PHP/9.81USD; MAA
= 271.52/6.64USD; AA = 270.05PHP/6.60USD). Cost per
precursor/early cancer lesion detected among 100,000
women screened is highest for SS and lowest for 
MAA (SS = 1,641,945.90PHP/40,152.25USD; CB =
1,289,000PHP/31,521.29USD; AA = 149,783.02PHP/
3,662.80USD; MAA = 116,515.82PHP/2,849.28USD).
Cost per life saved is lowest for MAA and highest for SS
(MAA = 6,191.88PHP/151.42USD; AA = 6,561.65PHP/
160.46USD; CB = 7,685.69PHP/187.95USD; SS =
8,921.00PHP/218.15USD). Variations in incidence of
precursor/early cervix cancer lesions, sensitivity of differ-
ent screening methods, target population coverage and
discount rate did not change the results of cost per life
saved due to cervical screening. CONCLUSION: Acetic
acid visualization of the cervix (with or without magniﬁ-
cation) is the cervical cancer screen method of choice for
the Philippines.
CANCER—Economic Outcomes
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OBJECTIVE: While results from several surveys of oncol-
ogy patients have found that depression is more preva-
lent among cancer patients than the general population,
few retrospective studies have been conducted to conﬁrm
these ﬁndings. This study compares rates of depression
among prostate cancer patients with controls, and exam-
ines the incremental burden of depression on healthcare
expenditures. METHODS: The study population con-
sisted of 2356 newly diagnosed prostate cancer patients
in 1999 or 2000 in the MarketScan database. A randomly
selected matched (age, insurance type, and geographic
region) group of non-cancerous males were selected as
controls (n = 7,495). Patients were followed for 12
months and classiﬁed as having depression if they had any
inpatient or outpatient claims with a depression diagno-
sis. Chi-square tests were used to compare depression
rates, as well as to investigate if cancer treatment regimen
was associated with increased risk of depression. Expen-
ditures accumulated during the study period were 
compared among prostate cancer patients using 
Mann-Whitney U-tests. RESULTS: The mean age of the
study population was 68 years and over half (58%) of
the patients had Medicare coverage. The rate of depres-
sion among prostate cancer patients was approximately
twice that of the matched non-cancerous population
(2.97% vs. 1.83%, p = 0.0008). Prostate cancer patients
with depression had higher mean inpatient ($14,031 vs.
$7,345, p = 0.0183), outpatient ($8,807 vs. $8,041, p =
0.0434), drug ($2,868 vs. $1,601, p < 0.0001), and total
($30,220 vs. $21,415, p = 0.1125) expenditures than
prostate cancer patients without depression. Treatment
regimen was not a factor in depression status. CON-
